Analysis of PD-L1 expression in salivary duct carcinoma with its efficacy as a tumor marker
10.21593/kjhno/2019.35.1.13
- Author:
Yong Ju LEE
1
;
Yoon Woo KOH
;
Sun Och YOON
;
Hyang Joo RYU
;
Hye Ryun KIM
;
Hyang Ae SHIN
Author Information
1. Yonsei University College of Medicine, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Salivary Duct Cancer;
Programmed death ligand 1
- MeSH:
Humans;
Immunotherapy;
Prognosis;
Receptors, Death Domain;
Salivary Ducts;
Salivary Gland Neoplasms;
Survival Rate
- From:
Korean Journal of Head and Neck Oncology
2019;35(1):13-20
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND/OBJECTIVES: Despite multiple approaches of treatments for salivary duct carcinoma, there has been a need for more successful treatment methods because of its poor prognosis. Treatment options like immunotherapy using new technologies have been attempted. Based on recent study results indicating that targeting programmed death receptors are effective in treating various cancers, this study aimed to identify the frequency of PD-L1 expression and its impact on survival rate in salivary duct carcinoma.MATERIALS #SPCHAR_X0026; METHODS: We studied 33 patients with salivary gland cancer who were available for histologic specimens. We examined the expression of PD-L1 in the tissues and analyzed the association with the survival rate and the association with various clinical parameters.RESULTS: According to this study and review of similar studies, we discovered that the expression of PD-L1 in salivary duct carcinoma was lower than other types of cancers. The impact of PD-L1 on survival rate also showed inconsistency in salivary duct carcinoma.CONCLUSION: Immunotherapy by PD-1/PD-L1 checkpoint blockade in salivary duct carcinoma needs further evaluation for clinical application.
